Neuronal autophagy and neurodevelopmental disorders
They operate through largely distinct, yet potentially complementary, pathways
Kanthasamy, [email protected] This article was submitted to Gut-Brain Axis, a section of the journal Frontiers in Neuroscience Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
doi:10.1210/jc.2009-1062 30
While many GLP-1 drugs are currently covered by Medicare Part D and Medicaid when prescribed for certain conditions, such as type 2 diabetes, Medicare has been prohibited from covering the drugs solely for weight loss, and only 16 state Medicaid programs, not including Arkansas, cover GLP-1 therapies for obesity treatment